Schroder Investment Management Group Acquires 19,562 Shares of IDEXX Laboratories, Inc. (IDXX)
Schroder Investment Management Group grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 29.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 86,418 shares of the company’s stock after acquiring an additional 19,562 shares during the period. Schroder Investment Management Group owned 0.10% of IDEXX Laboratories worth $13,341,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of IDXX. Strs Ohio grew its position in IDEXX Laboratories by 0.7% in the second quarter. Strs Ohio now owns 5,929 shares of the company’s stock worth $957,000 after acquiring an additional 41 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of IDEXX Laboratories by 25.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 3,922 shares of the company’s stock worth $633,000 after buying an additional 792 shares during the period. CIBC Asset Management Inc boosted its holdings in shares of IDEXX Laboratories by 3.0% during the 2nd quarter. CIBC Asset Management Inc now owns 10,939 shares of the company’s stock worth $1,766,000 after buying an additional 316 shares during the period. Sei Investments Co. boosted its holdings in shares of IDEXX Laboratories by 94.0% during the 2nd quarter. Sei Investments Co. now owns 39,344 shares of the company’s stock worth $6,351,000 after buying an additional 19,067 shares during the period. Finally, Retirement Systems of Alabama boosted its holdings in shares of IDEXX Laboratories by 0.4% during the 2nd quarter. Retirement Systems of Alabama now owns 42,726 shares of the company’s stock worth $6,897,000 after buying an additional 187 shares during the period. 86.80% of the stock is owned by institutional investors.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $159.99 on Thursday. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a 1-year low of $113.92 and a 1-year high of $173.01. The firm has a market cap of $13,893.94, a price-to-earnings ratio of 53.64, a price-to-earnings-growth ratio of 2.41 and a beta of 0.42.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same period in the prior year, the firm earned $0.62 EPS. The business’s revenue was up 9.7% on a year-over-year basis. equities research analysts predict that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.
In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 54,000 shares of the stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total value of $8,171,280.00. Following the completion of the sale, the chairman now directly owns 1,064,573 shares of the company’s stock, valued at approximately $161,091,186.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Giovani Twigge sold 2,000 shares of the stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 110,000 shares of company stock valued at $16,686,200. Insiders own 2.77% of the company’s stock.
IDXX has been the subject of several recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a report on Monday, August 21st. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, August 22nd. Bank of America raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a report on Wednesday, August 23rd. Finally, Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. IDEXX Laboratories presently has an average rating of “Hold” and an average price target of $173.67.
ILLEGAL ACTIVITY NOTICE: “Schroder Investment Management Group Acquires 19,562 Shares of IDEXX Laboratories, Inc. (IDXX)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/schroder-investment-management-group-acquires-19562-shares-of-idexx-laboratories-inc-idxx/1748772.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.